Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
-
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
-
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
-
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
-
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
-
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
-
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
-
The Serum Institute of India (SII).
-
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
Latest shares articles
Ratings and Reviews
Ratings and Reviews
